drugset / Trial / NCT05485987
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.
Timeline
- Start
- 2022-10-12
- Primary completion
- 2024-08-29
- Completion
- 2024-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vatiquinone | Small molecule | 15 mg/kg | Oral |
| Subject | Vatiquinone | Small molecule | 200 mg | Oral |